Primary study period 2013–2017 | Secondary study period 2009–2013 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total eligible people, n | Attendees, n | % | Non-attendees, n | % | Total eligible people, n | Attendees, n | % | Non-attendees, n | % | ||
Total | 3 492 816 | 590 218 | — | 2 902 598 | — | Total | 3 427 380 | 300 975 | — | 3 126 405 | — |
QRisk2 recorded | 1 151 422 | 522 571 | 88.5 | 628 851 | 21.7 | QRisk2 recorded | 469 349 | 231 066 | 76.8 | 238 283 | 7.6 |
QRisk2 not recorded | 2 341 394 | 67 647 | 11.5 | 2 273 747 | 78.3 | QRisk2 not recorded | 2 958 031 | 69 909 | 23.2 | 2 888 122 | 92.4 |
<5% | 645 811 | 276 093 | 52.8 | 369 718 | 58.8 | <5% | 237 240 | 84 578 | 36.6 | 152 662 | 64.1 |
5–9% | 276 870 | 128 515 | 24.6 | 148 355 | 23.6 | 5–9% | 107 232 | 58 962 | 25.5 | 48 270 | 20.3 |
10–14% | 128 159 | 63 629 | 12.2 | 64 530 | 10.3 | 10–14% | 59 340 | 39 018 | 16.9 | 20 322 | 8.5 |
15–19% | 62 682 | 32 466 | 6.2 | 30 216 | 4.8 | 15–19% | 35 534 | 25 310 | 11.0 | 10 224 | 4.3 |
≥20% | 37 900 | 21 868 | 4.2 | 16 032 | 2.5 | ≥20% | 30 003 | 23 198 | 10.0 | 6805 | 2.9 |
CVD = cardiovascular disease.